Committed to Developing Products that
Provide Meaningful Improvements Over the Standard of Care in Psychiatry
Therapeutic Area:
Central Nervous System (CNS)
Austin, TX
  • Edgemont Pharmaceuticals was a specialty pharmaceutical company focused on developing and commercializing new formulations of widely-prescribed products where clear clinical need exists, for the treatment of psychiatric disorders.
  • Over the course of Vatera’s investment, Edgemont launched FXT60 and ForfivoXL, two novel formulations of antidepressant products that lower the pill burden for a patient to meet daily dosing requirements.
  • Edgemont sought to improve psychiatry treatment outcomes by reducing side effects, increasing patient compliance and expanding the dosing options available to treat psychiatric conditions.
  • VHP initially invested in Edgemont in December 2011. In December 2016, Edgemont successfully sold its marketed assets FXT60 and ForfivoXL.